
AKUMS DRUGS & PHARMACEUTICALS LTD.

(O) Plot No. 131 to 133, Block-C, Mangolpuri Ind. Area, Phase-I, (Adjoining CBSE Office) Delhi - 110083 (INDIA).

www.akums.in

□ akumsho@akums.net





+91-11-69041000

CIN: L24239DL2004PLC125888

Ref: Akums/Exchange/2025-26/35

August 08, 2025

To, **The Listing Department National Stock Exchange of India Ltd** Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051

To, The Listing Department **BSE Limited** Rotunda Building, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai -400 001

Scrip Code: 544222

Symbol: AKUMS

Sub: Press Release

Respected Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a copy of press release is enclosed herewith.

This is for your kind information and record.

Thanking You

For Akums Drugs and Pharmaceuticals Limited

Dharamvir Malik Company Secretary & Compliance Officer

Encl: as above

Akums reports Q1 FY26 with 19% YoY Adj EBITDA growth; Achieves 1,000 DCGI approvals

New Delhi, August 2025: Akums Drugs and Pharmaceuticals Limited, largest India-focused contract development and manufacturing organization (CDMO), has announced its consolidated financial results for the quarter ended June 30, 2025. This quarter continued to display strong performance with healthy growth in Adj EBITDA and Adj PAT.

In Q1 FY26, Akums reported total income of ₹1,051 crore, with healthy Adj EBITDA of ₹156 crore reflecting a robust 19.1% year-on-year (YoY) growth. The margins improved to 14.8% from 12.7% last year, a 208 bps improvement.

During this quarter, the company achieved a key milestone of reaching 1,000 Drug Controller General of India (DCGI) approvals, with 27 fresh approvals in this quarter. The DCGI approvals assist the company in enhancing its product mix, building a differentiated and research-driven portfolio. Additionally, the company also received a patent for its extended-release combination formulation of Doxylamine and Pyridoxine developed using the company's tablet in tablet technology.

As part of Akums' strategic vision to establish itself as a leading global CDMO, the company received its first European dossier approval for Rivaroxaban. It also filed its first dossier of Dapagliflozin combination in Switzerland. Both these new products hold significant market potential. The commercialization of the European contract continues to be on track and the company will commence commercial supplies from April 2027.

Akums received €100 million as part consideration for the European contract during Q1 of the current financial year. As a result, the company is at a cash surplus of ₹1,518 crore. The strong liquidity position provides a robust foundation for Akums to strategically scale up its business operations through both organic growth initiatives and inorganic opportunities.

Segmental Performance Overview

Akums' flagship business, CDMO, contributed \sim 79% to the group turnover with an EBITDA of 14.7% in Q1 FY 26. The company's domestic branded formulation business segment reported \sim 3% YoY growth while international branded formulation business grew by \sim 2% YoY. Trade generics and API segment continue to be in operational loss this quarter, though, through the management efforts, the losses are gradually reducing.

Commenting on the results, Mr. Sanjeev Jain, Managing Director, said:

"This date marks just over one year since we got listed. We continue to work towards strengthening the organization with a focus on long term growth. Our commitment to becoming a global CDMO player remains steadfast. The recent filings along with the planned global approvals of other facilities are setting up us in that endeavor."

Mr. Sandeep Jain, Managing Director, added:

"We continue to deliver strong performance despite the industry headwinds of decreasing API prices and muted volume growth. With a sustained focus on R&D, we have been able to deliver robust growth. Achieving 1,000 DCGI approvals is a key milestone that stands out Akums from its peers, allowing Akums

to offer margin accretive differentiated offerings. We remain focused on strengthening our CDMO leadership, scaling high-value capabilities, and driving operational excellence. Backed by a strong pipeline and prudent capital allocation, we are well-positioned to deliver sustainable and profitable growth in the years ahead."

Extract of Consolidated financial results

Particulars (Rs Cr)	Q1 FY 26	Q4 FY 25	Q1 FY 25
Revenue	1,024	1,055	1,019
Other income	27	18	7
Total income	1,051	1,073	1,026
Cost of goods sold	582	639	596
Employee Cost	176	184	176
Other Expenses	137	139	123
Adj EBITDA	156	111	131
Adj EBITDA Margin	14.8%	10.4%	12.7%
Adj PAT	65	44	57
Adj PAT Margin	6.2%	4.1%	5.6%

Definitions

- Adjusted EBITDA has been calculated as the sum of profit for the quarter, tax expenses, finance costs, depreciation and amortization expense, fair value changes to financial instruments, and exceptional items.
- Adjusted PAT is calculated as the profit for the quarter plus fair value changes to financial instruments less deferred tax created on brought forward losses.
- CDMO: Contract Development and Manufacturing Operations
- API: Active Pharmaceutical Ingredients

For further information, please contact: IR Desk

Akums Drugs and Pharmaceuticals Ltd investors@akums.net/ankit.jain@akums.net